Balaxi Pharmaceuticals Limited (BALAXI) AI Stock Analysis

• Market Cap: ₹990.42M
• Dividend Yield: N/A
• Average Volume (3M): 75.37K
• Price to Earnings (P/E): 112.0
• Beta (1Y): 0.97
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IN
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): N/A
• Shares Outstanding: 55,207,500
• 10 Day Avg. Volume: 158,740
• 30 Day Avg. Volume: 75,367
• PEG Ratio: -0.01
• Price to Book (P/B): 1.60
• Price to Sales (P/S): 1.28
• P/FCF Ratio: -6.29
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 62 Neutral
• Price Target: ₹19.00 ▼(-29.79% Downside)
• Action: Reiterated Date: 02/18/26
• Date: Action: Reiterated 02/18/26

The score is driven primarily by decent underlying financial strength (growth and a relatively solid balance sheet) but tempered by negative free cash flow and earnings volatility. Technicals are weak with a pronounced downtrend, partially offset by oversold readings. Valuation is supportive due to a low P/E.

Positive Factors

Revenue Growth

Consistent top-line growth indicates expanding market penetration for Balaxi's marketed pharmaceutical formulations. Durable revenue expansion supports reinvestment, scale benefits and margin stability over 2–6 months, underpinning operational leverage despite earnings noise.

Margin Quality

Healthy gross and EBIT margins show the company controls costs across manufacturing, sourcing, and distribution. Sustainable margin levels imply pricing power, efficient operations and ability to absorb input cost swings, supporting earnings resilience over coming months.

Balance Sheet Strength

A strong equity ratio and historically low debt-to-equity provide financial flexibility to fund working capital and strategic initiatives. This capital structure reduces refinancing risk and gives the company time to address temporary cashflow weakness without immediate equity dilution.

Negative Factors

Negative Free Cash Flow

Negative free cash flow driven by higher capex and negative operating cash flow erodes internally generated liquidity, increasing dependence on external financing. Over 2–6 months this pressure can constrain investments, raise financing costs, or require asset sales if not corrected.

Earnings Volatility

Volatile net income undermines predictability of earnings and cash generation. For stakeholders this raises forecasting risk, complicates reinvestment plans or dividend policy, and may increase the cost of capital or cautious credit terms over the medium term.

Rising Debt

A substantial increase in total debt in 2025 raises leverage and interest obligations. Coupled with negative operating cash flow, this elevates solvency and refinancing risk, potentially forcing austerity, higher borrowing costs, or asset disposals to stabilize the balance sheet.

Balaxi Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Balaxi Ventures Ltd. engages in the wholesale trading of pharmaceuticals, food products, and hardware. The company is headquartered in Hyderabad, Telangana. The Company’s products include pharmaceuticals products, food products and builders’ hardware products. The company operates through the operating segment international wholesale trading. Its pharmaceutical formulations and builders’ hardware products are contract manufactured from manufacturing plants in India. The firm offers a range of food and biscuit products under the brand name YAP. Its subsidiaries include Balaxi Global DMCC.

How the Company Makes Money

Balaxi Pharmaceuticals Limited primarily makes money by selling pharmaceutical products (formulations) to customers through its marketing and distribution activities, generating revenue from product sales. More specific details on the company’s revenue model (e.g., key product categories, geographic mix, customer segments, contract manufacturing/third-party sourcing arrangements, licensing income, or material partnerships) are not available in the provided context; therefore, null.

Balaxi Pharmaceuticals Limited Financial Statement Overview

Summary

Strong revenue growth and solid gross/EBIT margins support performance, and the balance sheet shows low leverage and a healthy equity ratio. Offsetting this, net income has been volatile and 2025 free cash flow turned negative with negative operating cash flow and higher capex, raising near-term financial risk.

Income Statement

Balaxi Pharmaceuticals has shown a strong revenue growth trajectory, with a notable increase from 2024 to 2025. The gross profit and EBIT margins are solid, reflecting good cost management and operational efficiency. However, the net profit margin has been inconsistent, with significant fluctuations in net income, indicating potential volatility in earnings.

Balance Sheet

The company's balance sheet shows a healthy equity ratio, indicating a strong capital structure with significant stockholders' equity relative to total assets. The debt-to-equity ratio is low, which minimizes financial risk. However, there has been a substantial increase in total debt in 2025, which could suggest a higher financial leverage moving forward.

Cash Flow

Balaxi Pharmaceuticals has faced challenges with negative free cash flow in 2025, driven by a significant increase in capital expenditures and operating cash flow turning negative. This raises concerns about cash management and sustainability of operations without external financing.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.76B	2.89B	2.41B	3.36B	2.79B	2.31B
Gross Profit	1.24B	1.27B	1.13B	1.34B	837.91M	591.85M
EBITDA	231.75M	305.64M	456.59M	603.82M	560.20M	449.86M
Net Income	144.99M	250.70M	-23.87M	459.63M	476.58M	381.37M
Balance Sheet
Total Assets	3.22B	3.10B	2.58B	2.40B	1.76B	996.80M
Cash, Cash Equivalents and Short-Term Investments	388.49M	394.00M	622.91M	282.17M	71.93M	16.69M
Total Debt	565.23M	534.25M	194.04M	133.06M	36.38M	36.59M
Total Liabilities	844.30M	786.06M	569.79M	567.89M	633.07M	347.00M
Stockholders Equity	2.38B	2.32B	2.01B	1.83B	1.13B	649.80M
Cash Flow
Free Cash Flow	25.78M	-589.01M	32.97M	-89.05M	68.00M	-25.53M
Operating Cash Flow	149.66M	-377.82M	48.66M	60.75M	341.44M	32.00K
Investing Cash Flow	-167.16M	-217.64M	-10.46M	-105.65M	-284.48M	-59.73M
Financing Cash Flow	11.99M	366.55M	302.54M	255.13M	-1.63M	36.46M

Balaxi Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 27.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BALAXI, the sentiment is Negative. The current price of 27.06 is above the 20-day moving average (MA) of 19.36, above the 50-day MA of 22.31, and below the 200-day MA of 38.14, indicating a bearish trend. The MACD of -1.22 indicates Negative momentum. The RSI at 35.06 is Neutral, neither overbought nor oversold. The STOCH value of 17.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BALAXI.

Balaxi Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIOFILCHEM	63 Neutral	₹496.51M	172.45	―	―	36.76%	433.63%
BALAXI	62 Neutral	₹990.42M	111.96	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LASA	44 Neutral	₹366.74M	-4.63	―	―	-20.40%	-59.20%
VIVIMEDLAB	39 Underperform	₹547.23M	-1.41	―	―	-22.42%	21.83%

Balaxi Pharmaceuticals Limited Corporate Events

Balaxi Pharma Opens One-Year Window to Dematerialise Legacy Physical Shares

Balaxi Pharmaceuticals Limited has notified the stock exchange that it has published newspaper advertisements announcing a special one-year window for the transfer and dematerialisation of physical shares. The window, effective from 5 February 2026 to 4 February 2027, applies to physical share certificates relating to transactions executed before 1 April 2019 and allows shareholders to lodge or re-lodge pending or earlier transfer and demat requests.

The initiative, undertaken in line with a recent SEBI circular, is aimed at helping investors regularise older physical shareholdings and migrate them into electronic form. By facilitating compliance with updated market regulations and improving share transfer efficiency, the move is expected to enhance transparency in the company’s shareholding structure and reduce operational frictions for legacy investors.